DIAGENS-B (02526.HK): Signs Three-Year Cooperation Framework Agreement with Anzhen'er on Provincial Medical Imaging AI Platform

NewTimeSpace News: On 11 September 2026, Hangzhou Diagens Biotechnology Co., Ltd. (stock code: 02526.HK) announced that it has entered into a cooperation framework agreement with Zhejiang Anzhen'er Medical Artificial Intelligence Technology Co., Ltd. (Anzhen'er) for a term of three years from the date of signing, covering cooperation in medical imaging artificial intelligence, primary-level imaging cloud services and medical data products. Anzhen'er is jointly funded by Hangzhou Iron and Steel Group and Ant Group and operates under the guidance of the Health Commission of Zhejiang Province as the operating entity of the National Artificial Intelligence Application Pilot Test Base (Medical) in Zhejiang, and is an independent third party of the Company.

Under the agreement, the parties intend to combine the Group's iMedImage® multimodal medical imaging capabilities with Anzhen'er's resources to build a provincial "digital-intelligent imaging" capability base covering pre-diagnosis consultation, imaging preliminary screening and report interpretation, to explore an imaging cloud service model under which examinations are conducted at the primary level, identification in the cloud and review at the provincial level, to jointly build a Zhejiang provincial cloud platform for AI-assisted medical imaging diagnosis, and to jointly develop high-quality medical datasets, artificial intelligence training corpora and research and data analytics products. The Company said that, as of the date of the announcement, no specific agreements have been entered into for specific cooperation projects, and the cooperation does not currently constitute any revenue or profit forecast or commitment of the Group.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.